Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mentice AB (publ) (MNTC.ST)
Gothenburg, SE
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.92% | +2.71% | -0.38% | -1.49% | -5.02% | -1.12% | -16.40% | -68.68% | -82.97% | -80.40% | -80.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-3.9% Q1'26: +14.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-59.7% Q1'26: +45.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-13.1% Q1'26: +41.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-11.9% Q1'26: -31.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-25.2% Q1'26: -93.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+9.9% Q1'26: +10.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-15.23× Q1'26: -0.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
149.37M
est: 165.85M (-9.9%)
|
137.50M
est: 158.55M (-13.3%)
|
185.06M
est: 176.19M (+5.0%)
|
217.95M
est: 226.43M (-3.7%)
|
273.61M
est: 280.53M (-2.5%)
|
290.33M
est: 294.57M (-1.4%)
|
279.09M
est: 271.64M (+2.7%)
|
309.50M
304.02M – 314.98M
+13.9% YoY
|
341.50M
337.98M – 345.02M
+10.3% YoY
|
372.00M
371.92M – 372.08M
+8.9% YoY
|
| EBITDA |
-13.88M
est: 4.95M (-380.4%)
|
-3.90M
est: 4.73M (-182.4%)
|
1.44M
est: 5.26M (-72.5%)
|
266.0K
est: 6.76M (-96.1%)
|
28.87M
est: 3.30M (+774.4%)
|
18.30M
est: 3.47M (+427.8%)
|
-1.72M
est: 3.20M (-153.7%)
|
3.64M
3.58M – 3.71M
+13.9% YoY
|
4.02M
3.98M – 4.06M
+10.3% YoY
|
4.38M
4.38M – 4.38M
+8.9% YoY
|
| EBIT |
-25.44M
est: -12.78M (-99.1%)
|
-18.05M
est: -12.22M (-47.7%)
|
-20.73M
est: -13.58M (-52.7%)
|
-22.67M
est: -17.45M (-29.9%)
|
1.17M
est: -26.10M (+104.5%)
|
-12.28M
est: -27.41M (+55.2%)
|
-33.06M
est: -25.27M (-30.8%)
|
-28.80M
-29.31M – -28.29M
-13.9% YoY
|
-31.77M
-32.10M – -31.45M
-10.3% YoY
|
-34.61M
-34.62M – -34.60M
-8.9% YoY
|
| Net Income |
-20.60M
est: -10.47M (-96.8%)
|
-13.09M
est: 1.90M (-790.1%)
|
-29.19M
est: -17.15M (-70.2%)
|
-30.67M
est: -24.11M (-27.2%)
|
-2.82M
est: -11.01M (+74.4%)
|
-18.42M
est: -18.63M (+1.1%)
|
-32.33M
est: -25.09M (-28.9%)
|
-6.31M
-6.53M – -1.91M
+74.8% YoY
|
8.95M
3.05M – 14.67M
+241.8% YoY
|
19.38M
13.35M – 26.58M
+116.7% YoY
|
| SGA |
50.83M
est: 103.66M (-51.0%)
|
40.25M
est: 99.10M (-59.4%)
|
47.19M
est: 110.12M (-57.1%)
|
192.33M
est: 141.52M (+35.9%)
|
237.06M
est: 158.91M (+49.2%)
|
240.54M
est: 166.86M (+44.2%)
|
—
est: 153.87M (-100.0%)
|
175.32M
172.22M – 178.43M
+13.9% YoY
|
193.45M
191.45M – 195.45M
+10.3% YoY
|
210.73M
210.68M – 210.77M
+8.9% YoY
|
| EPS |
-1.05
est: -0.41 (-156.7%)
|
-0.54
est: 0.07 (-828.2%)
|
-1.18
est: -0.67 (-76.0%)
|
-1.22
est: -0.94 (-29.5%)
|
-0.11
est: -0.39 (+71.9%)
|
-0.72
est: -0.66 (-8.7%)
|
-1.15
est: -0.89 (-28.9%)
|
-0.15
-0.23 – -0.07
+83.2% YoY
|
0.32
0.11 – 0.52
+310.0% YoY
|
0.71
0.47 – 0.95
+125.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Göran Malmberg | Advisor & Director | 4M | male |
| Frans Matthieu Venker | Group Chief Executive Officer & President | 4M | male |
| Edward Fält | Chief Strategy Officer | — | male |
| Henrik Storm | Chief Technology Officer | — | male |
| Jonatan Sjostrom | Chief Operating Officer | — | male |
| Martin Harris | Vice President of Marketing | — | male |
| Stacy Hammar | Corporate Marketing Manager of Medical Device | — | female |
| Dominic Steffel | Senior Product Manager | — | — |
| Ulrika Drotz Voksepp | Chief Financial Officer | — | female |
| Edward Falt | Chief Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MNTC.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
